Intestinal barrier dysfunction plays an integral role in arthritis pathology and can be targeted to ameliorate disease.
arthritis
gut mucosa
gut permeability
inflammation
therapy
Journal
Med (New York, N.Y.)
ISSN: 2666-6340
Titre abrégé: Med
Pays: United States
ID NLM: 101769215
Informations de publication
Date de publication:
09 07 2021
09 07 2021
Historique:
received:
04
02
2020
revised:
22
02
2021
accepted:
15
04
2021
entrez:
23
7
2021
pubmed:
24
7
2021
medline:
24
7
2021
Statut:
ppublish
Résumé
Evidence suggests an important role for gut-microbiota dysbiosis in the development of rheumatoid arthritis (RA). The link between changes in gut bacteria and the development of joint inflammation is missing. Here, we address whether there are changes to the gut environment and how they contribute to arthritis pathogenesis. We analyzed changes in markers of gut permeability, damage, and inflammation in peripheral blood and serum of RA patients. Serum, intestines, and lymphoid organs isolated from K/BxN mice with spontaneous arthritis or from wild-type, genetically modified interleukin (IL)-10R RA patients display increased levels of serum markers of gut permeability and We suggest that breakdown of gut-barrier integrity contributes to arthritis development and propose restoration of gut-barrier homeostasis as a new therapeutic approach for RA. Funded by Versus Arthritis (21140 and 21257) and UKRI/MRC (MR/T000910/1).
Sections du résumé
BACKGROUND
Evidence suggests an important role for gut-microbiota dysbiosis in the development of rheumatoid arthritis (RA). The link between changes in gut bacteria and the development of joint inflammation is missing. Here, we address whether there are changes to the gut environment and how they contribute to arthritis pathogenesis.
METHODS
We analyzed changes in markers of gut permeability, damage, and inflammation in peripheral blood and serum of RA patients. Serum, intestines, and lymphoid organs isolated from K/BxN mice with spontaneous arthritis or from wild-type, genetically modified interleukin (IL)-10R
FINDINGS
RA patients display increased levels of serum markers of gut permeability and
CONCLUSIONS
We suggest that breakdown of gut-barrier integrity contributes to arthritis development and propose restoration of gut-barrier homeostasis as a new therapeutic approach for RA.
FUNDING
Funded by Versus Arthritis (21140 and 21257) and UKRI/MRC (MR/T000910/1).
Identifiants
pubmed: 34296202
doi: 10.1016/j.medj.2021.04.013
pii: S2666-6340(21)00162-8
pmc: PMC8280953
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
864-883.e9Subventions
Organisme : Versus Arthritis
ID : 21140
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T000910/1
Pays : United Kingdom
Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
A.F. is co-founder and stockholder of Alba Therapeutics, a company developing treatments complementary to the gluten-free diet by exploiting gut permeability.
Références
J Rheumatol. 1991 Mar;18(3):389-93
pubmed: 1906938
Br J Rheumatol. 1986 May;25(2):162-6
pubmed: 3085760
Adv Immunol. 2014;122:177-210
pubmed: 24507158
J Cell Biol. 1986 Sep;103(3):755-66
pubmed: 3528172
Nat Commun. 2020 Apr 24;11(1):1995
pubmed: 32332732
Am J Physiol Gastrointest Liver Physiol. 2013 Sep 1;305(5):G357-63
pubmed: 23832516
Front Immunol. 2018 Jun 05;9:1270
pubmed: 29922293
Am J Physiol Gastrointest Liver Physiol. 2017 Mar 1;312(3):G171-G193
pubmed: 27908847
Clin Chem. 2008 Apr;54(4):697-704
pubmed: 18258668
Arthritis Rheumatol. 2017 May;69(5):964-975
pubmed: 27863183
Genome Med. 2016 Apr 21;8(1):43
pubmed: 27102666
J Clin Med. 2019 Nov 01;8(11):
pubmed: 31683983
Cell Metab. 2020 Apr 7;31(4):837-851.e10
pubmed: 32213346
Mult Scler. 2020 Oct;26(11):1340-1350
pubmed: 31317818
J Immunol. 2003 Dec 1;171(11):6164-72
pubmed: 14634132
J Clin Med. 2019 May 16;8(5):
pubmed: 31100891
J Proteome Res. 2017 Jan 6;16(1):346-354
pubmed: 27627584
FASEB J. 2005 Jun;19(8):923-33
pubmed: 15923402
Mult Scler. 2017 Mar;23(3):442-446
pubmed: 27270497
J Clin Med. 2017 Jun 09;6(6):
pubmed: 28598360
J Rheumatol. 1985 Apr;12(2):299-305
pubmed: 4032403
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
pubmed: 19801464
J Immunol Res. 2017;2017:4835189
pubmed: 28948174
Nat Commun. 2016 May 19;7:11627
pubmed: 27193261
Cell. 1996 Nov 29;87(5):811-22
pubmed: 8945509
J Immunol. 2014 Feb 1;192(3):1267-76
pubmed: 24367025
Biomed Rep. 2013 Mar;1(2):177-184
pubmed: 24648915
J Rheumatol. 1991 Mar;18(3):394-400
pubmed: 1906939
N Engl J Med. 2011 Dec 8;365(23):2205-19
pubmed: 22150039
Ann Rheum Dis. 2017 Jun;76(6):1123-1132
pubmed: 28069576
Nat Mater. 2021 Feb;20(2):250-259
pubmed: 32895507
Scand J Rheumatol. 1997;26(2):92-8
pubmed: 9137322
J Immunol. 2016 Feb 15;196(4):1550-7
pubmed: 26783341
Mediators Inflamm. 2015;2015:628340
pubmed: 26457007
Liver Int. 2019 Feb;39(2):371-381
pubmed: 30269440
Elife. 2013 Nov 05;2:e01202
pubmed: 24192039
Immunity. 2004 Oct;21(4):527-38
pubmed: 15485630
Am J Pathol. 2018 May;188(5):1183-1194
pubmed: 29454749
Lancet. 1984 Nov 24;2(8413):1171-4
pubmed: 6150232
Diabetologia. 2006 Dec;49(12):2824-7
pubmed: 17028899
Int Immunol. 2000 Feb;12(2):133-9
pubmed: 10653848
J Allergy Clin Immunol. 2009 Jul;124(1):3-20; quiz 21-2
pubmed: 19560575
Physiol Rev. 2011 Jan;91(1):151-75
pubmed: 21248165
J Mol Med (Berl). 2017 Sep;95(9):927-934
pubmed: 28707083
Nat Med. 2014 Nov;20(11):1334-9
pubmed: 25326801
J Rheumatol. 2017 Nov;44(11):1624-1631
pubmed: 28916545
Int J Mol Sci. 2018 Sep 27;19(10):
pubmed: 30261687
Arthritis Rheumatol. 2016 Nov;68(11):2646-2661
pubmed: 27333153
Cell. 2004 Jul 23;118(2):229-41
pubmed: 15260992
Blood. 2001 Nov 1;98(9):2626-32
pubmed: 11675330
J Clin Invest. 2008 Mar;118(3):1132-42
pubmed: 18259614
JCI Insight. 2019 Jul 11;4(13):
pubmed: 31292292
Int J Clin Exp Pathol. 2014 Jul 15;7(8):4557-76
pubmed: 25197329
J Biol Chem. 2009 Oct 16;284(42):29205-17
pubmed: 19690347
Nat Med. 2015 Aug;21(8):895-905
pubmed: 26214836
Nat Commun. 2018 Feb 15;9(1):684
pubmed: 29449556
Cytoskeleton (Hoboken). 2016 Apr;73(4):163-79
pubmed: 26972322
Gastroenterology. 2006 Oct;131(4):1153-63
pubmed: 17030185
Immunity. 2010 Jun 25;32(6):815-27
pubmed: 20620945
Clin Chim Acta. 2005 Feb;352(1-2):15-35
pubmed: 15653098
Front Med (Lausanne). 2018 Dec 14;5:349
pubmed: 30619860
Gut. 2007 Jan;56(1):61-72
pubmed: 16822808
Ann N Y Acad Sci. 2012 Jul;1258:25-33
pubmed: 22731712
J Exp Med. 2016 Jun 27;213(7):1223-39
pubmed: 27325889
Int J Mol Sci. 2018 Jul 31;19(8):
pubmed: 30065229
Biomolecules. 2019 Jul 31;9(8):
pubmed: 31370242
Microorganisms. 2018 Aug 02;6(3):
pubmed: 30072673
Gastroenterology. 2015 Jun;148(7):1311-9.e6
pubmed: 25683116